SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility, prompting discussions about a potential market correction or even the start of a bear market. Fed Governor Lisa Cook's comments regarding high valuations are being cited as a possible catalyst for the downturn. Community sentiment is mixed, with both bulls and bears actively trading the volatility and debating potential bottom levels and future direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is experiencing a sell-off, leading to widespread discussion about potential market manipulation and whether the AI bubble is bursting. Community sentiment is largely negative, with many questioning the high valuations and pointing to potential downside. Some traders are expressing frustration, while others are seizing the opportunity to buy the dip or profit from short positions.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The $QQQ is experiencing significant volatility, driven by an intense intraday sell-off despite initially gapping up on strong earnings from major tech companies. Community sentiment is shifting rapidly, with many traders expressing shock and questioning the market's fundamentals as the index reverses sharply. Discussions revolve around potential manipulation, the influence of macroeconomic factors, and whether this signals a broader market correction or just a short-term pullback.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, sparking debate about potential support levels and whether this signals the end of the current cycle. Community members are discussing Michael Saylor's position and potential liquidations, while others point to broader market factors and potential manipulation. The conversation includes opinions on Bitcoin's role as a store of value and its impact on the wider market.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amid a broader tech sector pullback and ahead of Nvidia's earnings report, with some traders expressing concerns about an AI bubble. The community is debating whether the dip presents a buying opportunity or if further declines are expected, while others are highlighting AMD's partnerships and potential for growth in the AI space. Discussions also include potential price targets and the impact of macroeconomic factors on the stock's performance.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as it amplifies Bitcoin's movements, with concerns rising about debt leverage and potential liquidation. Community discussions revolve around whether the stock is overvalued and how much further it could drop, with some anticipating a significant decline. Broader market commentary suggests potential risks tied to hedge fund activity and overall market valuations which may impact Strategy.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings Corp is trending due to a shift in business strategy and community speculation around a potential short squeeze. Traders are actively debating float size, short interest, and the possibility of a GME-like scenario, while others express concerns about pump-and-dump schemes and dilution. High volatility and trading volume contribute to the ongoing discussion.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community debates its future amidst market volatility and the launch of new ETFs; traders are actively discussing potential price floors and whether upcoming events will act as catalysts. Community members are split on whether to buy the dip or brace for further declines, while some question XRP's utility and its correlation with Bitcoin's price movements.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as traders digest a recent price target increase from UBS, countered by potential concerns over capex spending. Community discussion revolves around the sustainability of the rally and whether the stock is currently overbought, especially in light of the broader AI-driven memory demand narrative. Some traders are pointing to potential short-term pullback scenarios.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending downwards, with community members citing general market conditions and a delayed Neutron launch as catalysts for the dip, despite a recent successful launch and positive earnings report. The community is debating whether to buy the dip or brace for further declines, with some expressing frustration while others remain bullish on the company's long-term potential and are taking the opportunity to add to their positions. Some traders attribute the drop to short sellers and broader market trends.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candriam S.C.A. Sells 326,547 Shares of Nurix Therapeutics, Inc. $NRIX

Candriam S.C.A. lowered its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 55.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 6.9% - Time to Buy?

Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.9% - Should You Buy...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been given an average rating of "Moderate Buy" by the eighteen analysts that are presently covering the stock, Marketbeat...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Nurix Therapeutics shares fell more than 6% in after-hours trading on Thursday after the biotech firm reported a wider quarterly loss and lower revenue, reflecting higher research spending and changes in collaborations.In the third fiscal quarter ended Aug. 31, the San Francisco–based company posted a net loss of $86.4 million, or $1.03 a share, versus a loss of $49 million, or $0.67 a share, a year earlier.&nbsp;Revenue dropped to $7.9 million from $12.6 million, with income from its collaboration with Sanofi down following the expiration of the initial research period for certain targets. The decrease was partly offset by a higher percentage of completion of performance obligations related to its partnership with Pfizer.Research and development costs increased to $86.1 million from $55.5 million a year ago, mainly due to higher clinical, manufacturing and consulting costs related to increased enrollment in ongoing studies and preparation for late-stage trials.Nurix said it plans to launch pivotal trials next year for its BTK degrader bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The program will include a single-arm study for potential accelerated approval and a randomized Phase 3 trial for full approval.The company reported $428.8 million in cash and marketable securities at the end of the quarter and said it had enough capital to continue funding its programs and development partnerships with Gilead, Sanofi and Pfizer.Oppenheimer maintained an 'Outperform' rating on Nurix Therapeutics after lowering its price target to $28 from $30 following its results. The brokerage said shares have rebounded as investors become more comfortable with the regulatory strategy for bexobrutideg, particularly its prospects for accelerated approval.Oppenheimer noted that Nurix has been having ongoing discussions with the FDA under the drug’s Fast Track designation, and while management has continued to say publicly that accelerated approval will be a review issue, changes in the company’s latest corporate presentation suggest the FDA is&nbsp;on board with the plan, the firm added.One user noted that research and development spending had “gone way up,” suggesting it could shorten the company’s cash runway, but added there was still time to buy before shares begin to move higher ahead of pivotal bexobrutideg data.<stembedurl>https://stocktwits.com/oaksapollo/message/631728185</stembedurl>Another user said they had increased their position in Nurix, adding that they plan to keep buying as long as the stock remains below $10, and argued that bexobrutideg alone justifies the company’s roughly $685 million market capitalization.<stembedurl>https://stocktwits.com/oaksapollo/message/630831468</stembedurl><a href="https://stocktwits.com/symbol/NRIX">Nurix’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix’s stock (NRIX) has declined 42% so far in 2025. (Photo credit: Getty Images)

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

Oppenheimer cut its price target to $28 from $30 but kept a bullish view, citing FDA discussions and investor confidence in its Bexo program.

Equity

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the second quarter (Q2), bolstered by payments related to development milestones with both Sanofi and Gilead Sciences.The <a href="https://stocktwits.com/symbol/NRIX">Nurix Therapeutics stock</a> rose 7.9% on Wednesday and climbed another 13.9% after-hours.The company reported a net loss of $0.52 per share for the quarter ended May 31, above analyst estimates of a loss of $0.74 per share.&nbsp;Nurix also recorded revenue of $44.1 million, exceeding estimates of $17.5 million.&nbsp;A large chunk of that came from a $30 million license payment from Sanofi and a $5 million milestone tied to a Gilead-supported clinical program.Spending also increased as the company pushed ahead with its lead drug candidates.&nbsp;Research and development costs climbed to $78.1 million, up from $48.9 million a year earlier, while administrative expenses rose to $14.3 million from $11.7 million.The company shared new data from an early-stage trial of bexobrutideg, a BTK degrader it’s developing for certain blood cancers.&nbsp;Among patients with relapsed or treatment-resistant chronic lymphocytic leukemia, the treatment showed a response rate of 80.9%, with no serious heart issues or other safety red flags reported.Nurix finished the quarter with $485.8 million in cash and investments. The figure doesn’t include an additional $19 million it received shortly after the quarter ended from its partners.Looking ahead, the company plans to start late-stage trials of bexobrutideg later this year.&nbsp;It’s also expecting more clinical updates from other programs in its pipeline, including NX-2127 and NX-1607.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user noted that Nurix’s Q2 loss of $0.52 per share came in about 30% better than analyst expectations, and added that the stock could see another strong session tomorrow.<stembedurl>https://stocktwits.com/LongTrainRunning/message/620401421</stembedurl>Nurix Therapeutics’ stock has declined 32.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix Therapeutics (NRIX) reported stronger-than-expected results for the second quarter/ Photo credit: Getty Images

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRIX News

NRIXNurix Therapeutics Inc